Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 6
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers BJID
Nicodemo,Antonio Carlos.
We made an open label, multicenter, non-comparative study to assess the efficacy and safety of oral gatifloxacin, 400mg PO given once-daily during 7 to 14 days for the treatment of adult outpatients with community-acquired pneumonia at five Brazilian medical facilities. Among the 86 subjects available for clinical evaluation, 84 (98%) were cured. The bacteriological eradication and presumed eradication rate was 98% (52/53) among the 44 (51%) patients who were bacteriologically evaluated. Drug-related adverse events were reported by 27% of the patients, diarrhea being the most frequent, occurring in 12% of patients. Adverse events were considered mild (89%) or moderate (11%). We conclude that a 7-14 day course of gatifloxacin, 400mg PO given once daily is...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Gatifloxacin; Community-acquired pneumonia; Brazil.
Ano: 2003 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000100007
Imagem não selecionada

Imprime registro no formato completo
An open multicenter study of the use of gatifloxacin for the treatment of non-complicated acute bacterial rhinosinusitis in adults BJID
Weckx,L.L.M.; Campos,C.A.H.; Sakano,E.; Pignatari,S.S.N.; Figueiredo,C.R..
The bacteriological and clinical efficacy and the safety of gatifloxacin for the treatment of non-complicated acute rhinosinusitis was evaluated in 49 adult patients in an open-label multicenter study in Brazil. Patients under age 18, or with associated systemic diseases, were excluded. Diagnosis was based on symptoms, otorhinolaryngological examination, and X-rays of the sinus. At the first visit, all patients were treated with a single daily dose of 400 mg gatifloxacin for 10 days. Middle nasal meatus secretion was collected and sent for culture before and after treatment. Patients were all reevaluated at days 3 to 5; days + 1 to + 5 and 18 to 25 days + 7 to + 14 . Ninety three percent of the patients were considered clinically cured at the end of the...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Rhinossinusitis; Adults; Gatifloxacin.
Ano: 2005 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702005000200007
Imagem não selecionada

Imprime registro no formato completo
Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study BJID
Franca,Suelene Aires; Carvalho,Carlos Roberto Ribeiro.
OBJECTIVES: Evaluation of the effectiveness, safety and tolerability of gatifloxacin in the treatment of outpatients with community-acquired pneumonia (CAP). STUDY DESIGN: A prospective, multicenter, non-comparative clinical study carried out in Brazil. Voluntary, unpaid physician participation contributed to an unbiased study design. PATIENTS: Adult outpatients with clinical diagnosis of CAP. REGIMEN: Gatifloxacin, 400 mg PO once daily for 7 to 14 days. STUDY PROCEDURES: Initial clinical assessment, at the first day of gatifloxacin therapy; final evaluation after 7 to 14 days of treatment. RESULTS: According to the physicians' assessments 97.3% of patients were cured or improved after gatifloxacin treatment. The incidence of adverse events was low and the...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Gatifloxacin; Community-acquired pneunonia; Brazilian study.
Ano: 2002 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702002000400002
Imagem não selecionada

Imprime registro no formato completo
Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia BJID
Mendonça,J.S.; Yamaguti,A.; Corrêa,J.C.; Badaró,R..
Community-acquired pneumonia is very common, but some of the cases do require hospitalization for treatment, particularly when older patients and/or co-morbidities are involved; both "typical" and "atypical" respiratory pathogens take part etiologically, and there is increasing concern about the emergence of resistance. There is interest in therapeutic options that can: a) comprehend such a spectrum of bacteria and resistance; b) allow parenteral to oral sequential treatment. We made a multicenter, prospective and randomized trial to compare the "standard" treatment of ceftriaxone IV alone or in combination with erythromycin IV, followed by clarithromycin PO (ceftriaxone treatment arm), with gatifloxacin IV, followed by oral administration (gatifloxacin...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Ceftriaxone; Gatifloxacin; Pneumonias.
Ano: 2004 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702004000100006
Imagem não selecionada

Imprime registro no formato completo
Stability indicating RP-HPLC method for simultaneous determination of gatifloxacin and dexamethasone in binary combination BJPS
Razzaq,Syed Naeem; Ashfaq,Muhammad; Khan,Islam Ullah; Mariam,Irfana; Razzaq,Syed Saleem; Mustafa,Ghulam; Zubair,Muhammad.
Abstract In this study, conditions were optimized for development of a simple RP-HPLC method for simultaneous analysis of gatifloxacin and dexamethasone in different matrices like pharmaceuticals, human serum and urine. Good separation of gatifloxacin and dexamethasone from the induced degradation products was accomplished using C8 as stationary phase; 0.02 M phosphate buffer (pH 3.0) and methanol (42:58 v/v) as mobile phase. The concentration was measured with DAD at 270 nm. Linearity was observed in the range of 0.000040-0.000280 mol/L for gatifloxacin (r2≥0.999) and 0.000013-0.000091 mol/L for dexamethasone (r2≥0.999). Both the analyte peaks were completely separated from the peaks of induced degradation products as indicated by the peak purity index...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Gatifloxacin; Dexamethasone; High performance liquid chromatography; Validation; Plasma; Degradation products..
Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502017000100607
Imagem não selecionada

Imprime registro no formato completo
Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin BJID
Medeiros,Eduardo Alexandrino Servolo.
Respiratory tract infections have an important clinical and economic impact and they are the most common indication for antibiotic use in outpatient practice. This prospective, multicenter non-controlled trial assessed the efficacy and safety of gatifloxacin in the treatment of community-acquired respiratory tract infections. Patients were treated with a daily oral dose of gatifloxacin 400 mg for 7-14 days. The diagnosis of respiratory infection was made based on the clinical condition and/or radiologic findings. A total of 5,044 adult patients with community-acquired respiratory infections was treated with gatifloxacin in different centers in Brazil between March 1, 2001, and October 31, 2001. Among the 5,044 patients treated, 1,501 patients (29.76%) had...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Gatifloxacin; Community-acquired pneumonia; Acute sinusitis; Acute exacerbation of chronic bronchitis; Treatment of respiratory infections.
Ano: 2002 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702002000400001
Registros recuperados: 6
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional